Matchpoint’s lead asset is the oral T cell modulator MPT-062, which the biotech plans to advance into clinical development for autoimmune and inflammatory conditions next year.
Matchpoint’s lead asset is the oral T cell modulator MPT-062, which the biotech plans to advance into clinical development for autoimmune and inflammatory conditions next year.